Position,Locus,Disease,Allele,RNA,Homo plasmy,Hetero plasmy,Status,MitoTIP,GB Freq FL(CR),GB Seqs FL(CR),References
576,MT-CR,Hearing loss patient,A576G,noncoding MT-TF precursor,nr,nr,Reported,N/A,0.005%<br>(0.008%),3 (6),1
578,MT-TF,Unspecified patient from clinical lab / MS,T578C,tRNA Phe,nr,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=578&alt=C&quart=1'><u>78.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
582,MT-TF,Mitochondrial myopathy,T582C,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=582&alt=C&quart=2'><u>72.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
583,MT-TF,MELAS / MM & EXIT,G583A,tRNA Phe,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=583&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
586,MT-TF,"Extrapyramidal disorder with akinesia-rigidity, psychosis and SNHL",G586A,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=586&alt=A&quart=1'><u>89.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
590,MT-TF,EXIT+ataxia+RP,A590G,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=590&alt=G&quart=4'><u>16.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
593,MT-TF,Nonsyndromic hearing loss / LHON,T593C,tRNA Phe,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=593&alt=C&quart=4'><u>0.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T593C.html' target=_blank>0.491%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),268 (0),6
602,MT-TF,Axial myopathy with encephalopathy,C602T,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=602&alt=T&quart=1'><u>85.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
606,MT-TF,<a href='/MITOMAP/DiseaseList#Myoglobinuria'>Myoglobinuria</a>,A606G,tRNA Phe,+,+,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=606&alt=G&quart=2'><u>64.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.029%<br>(0.000%),16 (0),4
608,MT-TF,Tubulo-interstitial nephritis,A608G,tRNA Phe,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=608&alt=G&quart=2'><u>65.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
611,MT-TF,<a href='/MITOMAP/DiseaseList#MERRF'>MERRF</a>,G611A,tRNA Phe,nr,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=611&alt=A&quart=2'><u>51.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
616,MT-TF,Maternally inherited epilepsy / mito tubulointerstitial kidney disease (MITKD),T616C,tRNA Phe,+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=616&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),5
616,MT-TF,Maternally inherited epilepsy,T616G,tRNA Phe,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=616&alt=G&quart=1'><u>95.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
617,MT-TF,Carotid artery stenosis,G617A,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=617&alt=A&quart=1'><u>81.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
618,MT-TF,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,T618C,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=618&alt=C&quart=2'><u>65.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
618,MT-TF,Ptosis CPEO MM & EXIT,T618G,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=618&alt=G&quart=1'><u>77.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
622,MT-TF,EXIT & Deafness,G622A,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=622&alt=A&quart=3'><u>41.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
625,MT-TF,SNHL & Epilepsy,G625A,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=625&alt=A&quart=1'><u>81.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
628,MT-TF,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,C628T,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=628&alt=T&quart=3'><u>34.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.005%<br>(0.000%),3 (0),2
636,MT-TF,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A636G,tRNA Phe,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=636&alt=G&quart=4'><u>1.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.033%<br>(0.000%),18 (0),3
641,MT-TF,Epileptic Encephalopathy,A641T,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=641&alt=T&quart=2'><u>69.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
642,MT-TF,"Ataxia, PEO, deafness",T642C,tRNA Phe,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=642&alt=C&quart=2'><u>67.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
653,MT-RNR1,Atherosclerosis risk,G653del,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,2
653,MT-RNR1,Atherosclerosis study,G653GG,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
663,MT-RNR1,Coronary atherosclerosis risk,A663G,12S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A663G.html' target=_blank>2.837%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),1549 (0),1
669,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T669C,12S rRNA,+,-,Reported,N/A,0.174%<br>(0.000%),95 (0),4
721,MT-RNR1,Possibly LVNC-associated,T721C,12S rRNA,+,-,Reported,N/A,0.238%<br>(0.000%),130 (0),1
735,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A735G,12S rRNA,nr,nr,Reported,N/A,0.136%<br>(0.000%),74 (0),2
745,MT-RNR1,DEAF-associated,A745G,12S rRNA,+,-,Reported,N/A,0.064%<br>(0.000%),35 (0),1
750,MT-RNR1,SZ-associated,A750A,12S rRNA,+,-,Reported,N/A,1.694%<br>(0.000%),925 (0),3
773,MT-RNR1,Possible association with sepsis,T773C,12S rRNA,-,+,Reported,N/A,0.007%<br>(0.000%),4 (0),2
792,MT-RNR1,Increased risk of nonsyndromic deafness,C792T,12S rRNA,+,-,Reported,N/A,0.009%<br>(0.000%),5 (0),1
801,MT-RNR1,DEAF-associated,A801G,12S rRNA,+,-,Reported,N/A,0.013%<br>(0.000%),7 (0),1
827,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A827G,12S rRNA,+,-,Conflicting reports,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A827G.html' target=_blank>2.680%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),1463 (0),18
839,MT-RNR1,DEAF-associated,A839G,12S rRNA,+,-,Reported,N/A,0.013%<br>(0.000%),7 (0),1
850,MT-RNR1,Possibly LVNC-associated,T850C,12S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T850C.html' target=_blank>0.223%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),122 (0),1
856,MT-RNR1,LHON helper / AD / DEAF-associated,A856G,12S rRNA,+,-,Reported,N/A,0.031%<br>(0.000%),17 (0),3
869,MT-RNR1,found in 1 HCM patient,C869T,12S rRNA,+,-,Reported,N/A,0.134%<br>(0.000%),73 (0),1
921,MT-RNR1,Possibly LVNC-associated,T921C,12S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T921C.html' target=_blank>0.718%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),392 (0),2
955,MT-RNR1,Possible association with sepsis,A955C,12S rRNA,-,+,Reported,N/A,0.005%<br>(0.000%),3 (0),1
960,MT-RNR1,Possibly DEAF-associated,C960del,12S rRNA,+,-,Reported,N/A,0.095%<br>(0.000%),52 (0),1
960,MT-RNR1,Possibly DEAF-associated,C960CC,12S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/C960CC.html' target=_blank>0.544%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),297 (0),5
961,MT-RNR1,"DEAF, possibly LVNC-associated",T961C,12S rRNA,+,-,Unclear,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T961C.html' target=_blank>0.833%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),455 (0),9
961,MT-RNR1,DEAF / AD-associated / intellectual disability,T961delT+ / -C(n)ins,12S rRNA,+,+,Unclear,N/A,0.000%<br>(0.000%),,21
961,MT-RNR1,Possibly DEAF-associated,T961G,12S rRNA,+,-,Unclear,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T961G.html' target=_blank>0.361%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),197 (0),7
965,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T965TC,12S rRNA,+,-,Unclear,N/A,0.002%<br>(0.000%),1 (0),12
988,MT-RNR1,Possible DEAF risk factor,G988A,12S rRNA,nr,nr,Reported,N/A,0.081%<br>(0.000%),44 (0),1
990,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T990C,12S rRNA,+,-,Reported,N/A,0.064%<br>(0.000%),35 (0),1
1005,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1005C,12S rRNA,+,-,Unclear,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T1005C.html' target=_blank>0.451%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),246 (0),5
1027,MT-RNR1,DEAF-associated,A1027G,12S rRNA,+,-,Reported,N/A,0.029%<br>(0.000%),16 (0),1
1095,MT-RNR1,<a href='/MITOMAP/DiseaseList#SNHL'>SNHL</a>,T1095C,12S rRNA,+,+,Unclear,N/A,0.112%<br>(0.000%),61 (0),16
1116,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A1116G,12S rRNA,+,-,Reported,N/A,0.018%<br>(0.000%),10 (0),2
1119,MT-RNR1,Possible role in high altitude sickness,T1119C,12S rRNA,nr,nr,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T1119C.html' target=_blank>0.546%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),298 (0),1
1180,MT-RNR1,Possibly DEAF-associated,T1180G,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,2
1192,MT-RNR1,DEAF-associated,C1192A,12S rRNA,+,-,Reported,N/A,0.015%<br>(0.000%),8 (0),2
1192,MT-RNR1,DEAF-associated,C1192T,12S rRNA,+,-,Reported,N/A,0.024%<br>(0.000%),13 (0),1
1226,MT-RNR1,Possibly DEAF-associated,C1226G,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,2
1291,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1291C,12S rRNA,+,-,Unclear,N/A,0.101%<br>(0.000%),55 (0),3
1310,MT-RNR1,DEAF-associated,C1310T,12S rRNA,+,-,Reported,N/A,0.070%<br>(0.000%),38 (0),1
1331,MT-RNR1,DEAF-associated,A1331G,12S rRNA,+,-,Reported,N/A,0.018%<br>(0.000%),10 (0),1
1349,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1349G,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
1374,MT-RNR1,DEAF-associated,A1374G,12S rRNA,+,-,Reported,N/A,0.002%<br>(0.000%),1 (0),2
1382,MT-RNR1,Longevity / T2D susceptibility,A1382C,12S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A1382C.html' target=_blank>0.324%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),177 (0),3
1391,MT-RNR1,found in 1 HCM patient,T1391C,12S rRNA,+,+,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T1391C.html' target=_blank>0.223%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),122 (0),1
1420,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1420G,12S rRNA,+,+,Reported,N/A,0.000%<br>(0.000%),,1
1438,MT-RNR1,SZ-associated,A1438A,12S rRNA,+,-,Reported,N/A,5.001%<br>(0.000%),2730 (0),3
1452,MT-RNR1,DEAF-associated,T1452C,12S rRNA,+,-,Reported,N/A,0.095%<br>(0.000%),52 (0),1
1453,MT-RNR1,Possible DEAF risk factor,A1453G,12S rRNA,nr,nr,Reported,N/A,0.198%<br>(0.000%),108 (0),1
1492,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A1492C,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
1494,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,C1494T,12S rRNA,+,-,Cfrm,N/A,0.007%<br>(0.000%),4 (0),32
1517,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A1517C,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
1537,MT-RNR1,DEAF; intellectual disability,C1537T,12S rRNA,+,-,Reported,N/A,0.013%<br>(0.000%),7 (0),1
1544,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A1544T,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,2
1546,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A1546T,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,1
1554,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,G1554A,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,1
1555,MT-RNR1,DEAF; autism spectrum intellectual disability; possibly antiatherosclerotic,A1555G,12S rRNA,+,+,Cfrm,N/A,0.147%<br>(0.000%),80 (0),149
1556,MT-RNR1,found in 1 HCM patient,C1556T,12S rRNA,+,-,Reported,N/A,0.013%<br>(0.000%),7 (0),1
1575,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1575G,12S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,1
1577,MT-RNR1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,T1577G,12S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
1606,MT-TV,<a href='/MITOMAP/DiseaseList#AMDF'>AMDF</a>,G1606A,tRNA Val,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1606&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
1607,MT-TV,Suspected mito disease,T1607C,tRNA Val,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1607&alt=C&quart=4'><u>18.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),2
1612,MT-TV,LVNC (left ventricular noncompaction),C1612T,tRNA Val,+,-,Reported (VUS),<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1612&alt=T&quart=1'><u>76.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
1616,MT-TV,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,A1616G,tRNA Val,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1616&alt=G&quart=3'><u>36.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
1624,MT-TV,Leigh Syndrome,C1624T,tRNA Val,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1624&alt=T&quart=2'><u>68.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,6
1630,MT-TV,MNGIE-like disease / MELAS,A1630G,tRNA Val,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1630&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
1640,MT-TV,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,A1640G,tRNA Val,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1640&alt=G&quart=4'><u>6.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),1
1642,MT-TV,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,G1642A,tRNA Val,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1642&alt=A&quart=2'><u>74.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
1643,MT-TV,Late infantile onset fatal mito disease,A1643G,tRNA Val,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1643&alt=G&quart=3'><u>42.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
1644,MT-TV,Leigh Syndrome / HCM / MELAS,G1644A,tRNA Val,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1644&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
1644,MT-TV,Adult Leigh Syndrome,G1644T,tRNA Val,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1644&alt=T&quart=3'><u>48.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
1659,MT-TV,Movement Disorder,T1659C,tRNA Val,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1659&alt=C&quart=2'><u>69.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
1661,MT-TV,Charcot Marie Tooth (CMT),A1661G,tRNA Val,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=1661&alt=G&quart=3'><u>27.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
2156,MT-RNR2,Possible association with sepsis,A2156AA,16S rRNA,-,+,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A2156AA.html' target=_blank>0.361%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),197 (0),8
2158,MT-RNR2,Reduced risk PD,T2158C,16S rRNA,nr,nr,Reported,N/A,0.377%<br>(0.000%),206 (0),2
2336,MT-RNR2,Hypertrophic cardiomyopathy,T2336C,16S rRNA,+,-,Reported,N/A,0.000%<br>(0.000%),,2
2352,MT-RNR2,Possibly LVNC-associated,T2352C,16S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T2352C.html' target=_blank>2.337%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),1276 (0),3
2361,MT-RNR2,Possibly LVNC-associated,G2361A,16S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G2361A.html' target=_blank>0.256%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),140 (0),1
2492,MT-RNR2,Possible association with sepsis,G2492A,16S rRNA,-,+,Reported,N/A,0.002%<br>(0.000%),1 (0),2
2639,MT-RNR2,Rare mutation in a single POAG patient,C2639A,16S rRNA,+,-,Reported,N/A,0.002%<br>(0.000%),1 (0),1
2647,MT-RNR2,Possible association with sepsis,G2647A,16S rRNA,-,+,Reported,N/A,0.002%<br>(0.000%),1 (0),2
2648,MT-RNR2,Rett Syndrome,T2648C,16S rRNA,nr,nr,Reported,N/A,0.002%<br>(0.000%),1 (0),1
2706,MT-RNR2,Increased risk of T2DM in haplogroup H,A2706A,16S rRNA,+,-,Reported,N/A,21.169%<br>(0.000%),11557 (0),1
2755,MT-RNR2,Possibly LVNC-associated,A2755G,16S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A2755G.html' target=_blank>0.469%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),256 (0),3
2806,MT-RNR2,Possible association with sepsis,T2806A,16S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,1
2835,MT-RNR2,Rett Syndrome,C2835T,16S rRNA,-,+,Reported,N/A,0.114%<br>(0.000%),62 (0),2
3010,MT-RNR2,Cyclic Vomiting Syndrome with Migraine / high altitude adaptation,G3010A,16S rRNA,+,-,Reported,N/A,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G3010A.html' target=_blank>14.655%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),8001 (0),9
3054,MT-RNR2,Possible association with sepsis,G3054A,16S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,2
3090,MT-RNR2,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G3090A,16S rRNA,-,+,Reported,N/A,0.004%<br>(0.000%),2 (0),1
3093,MT-RNR2,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,C3093G,16S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,2
3096,MT-RNR2,Possible association with sepsis,T3096C,16S rRNA,-,+,Reported,N/A,0.024%<br>(0.000%),13 (0),3
3098,MT-RNR2,Possible association with sepsis,T3098C,16S rRNA,-,+,Reported,N/A,0.000%<br>(0.000%),,2
3111,MT-RNR2,Migraine,A3111T,16S rRNA,+,-,Reported,N/A,0.011%<br>(0.000%),6 (0),1
3196,MT-RNR2,<a href='/MITOMAP/DiseaseList#ADPD'>ADPD</a>,G3196A,16S rRNA,+,+,Reported,N/A,0.027%<br>(0.000%),15 (0),3
3236,MT-TL1,Sporadic bilateral optic neuropathy / hearing loss,A3236G,tRNA Leu (UUR),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3236&alt=G&quart=3'><u>37.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),4
3242,MT-TL1,MM / HCM+renal tubular dysfunction,G3242A,tRNA Leu (UUR),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3242&alt=A&quart=4'><u>18.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
3243,MT-TL1,MELAS / Leigh Syndrome / DMDF / MIDD / SNHL / CPEO / MM / FSGS / ASD / Cardiac+multi-organ dysfunction,A3243G,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3243&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),439
3243,MT-TL1,MM / MELAS / SNHL / CPEO,A3243T,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3243&alt=T&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,8
3244,MT-TL1,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,G3244A,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3244&alt=A&quart=3'><u>41.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.011%<br>(0.000%),6 (0),4
3249,MT-TL1,<a href='/MITOMAP/DiseaseList#KSS'>KSS</a>,G3249A,tRNA Leu(UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3249&alt=A&quart=3'><u>39.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3250,MT-TL1,MM / CPEO,T3250C,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3250&alt=C&quart=3'><u>33.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),12
3251,MT-TL1,MM / MELAS with chorea-ballism,A3251G,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3251&alt=G&quart=3'><u>43.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
3252,MT-TL1,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,A3252G,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3252&alt=G&quart=3'><u>39.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
3252,MT-TL1,<a href='/MITOMAP/DiseaseList#EXIT'>EXIT</a>,A3252T,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3252&alt=T&quart=3'><u>39.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
3253,MT-TL1,Maternally inherited hypertension,T3253C,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3253&alt=C&quart=4'><u>0.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),3
3254,MT-TL1,Gestational Diabetes (GDM),C3254A,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3254&alt=A&quart=2'><u>60.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.051%<br>(0.000%),28 (0),1
3254,MT-TL1,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,C3254G,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3254&alt=G&quart=2'><u>60.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3254,MT-TL1,CPEO / poss. hypertension factor,C3254T,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3254&alt=T&quart=3'><u>25.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.031%<br>(0.000%),17 (0),5
3255,MT-TL1,MERRF / KSS overlap,G3255A,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3255&alt=A&quart=1'><u>75.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
3256,MT-TL1,MELAS; possible atherosclerosis risk,C3256T,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3256&alt=T&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,20
3258,MT-TL1,MELAS / Myopathy,T3258C,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3258&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),5
3260,MT-TL1,MMC / MELAS,A3260G,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3260&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,13
3264,MT-TL1,<a href='/MITOMAP/DiseaseList#DM'>DM</a>,T3264C,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3264&alt=C&quart=3'><u>47.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3271,MT-TL1,MELAS / DM,T3271C,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3271&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,29
3273,MT-TL1,PEM / retinal dystrophy in MELAS,T3273del,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3273&alt=:&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3273,MT-TL1,Ocular myopathy,T3273C,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3273&alt=C&quart=2'><u>71.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3274,MT-TL1,Neuropsychiatric syndrome + cataract,A3274G,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3274&alt=G&quart=1'><u>77.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
3275,MT-TL1,<a href='/MITOMAP/DiseaseList#LHON'>LHON</a>,C3275A,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3275&alt=A&quart=4'><u>2.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),4
3275,MT-TL1,Metabolic syndrome and polycystic ovary syndrome / LHON,C3275T,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3275&alt=T&quart=4'><u>2.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),6
3277,MT-TL1,Poss. hypertension factor,G3277A,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3277&alt=A&quart=4'><u>2.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.062%<br>(0.000%),34 (0),2
3278,MT-TL1,Poss. hypertension factor,T3278C,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3278&alt=C&quart=4'><u>13.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.026%<br>(0.000%),14 (0),3
3280,MT-TL1,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,A3280G,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3280&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,6
3283,MT-TL1,Late onset ocular myopathy,G3283A,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3283&alt=A&quart=2'><u>58.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
3287,MT-TL1,<a href='/MITOMAP/DiseaseList#Encephalomyopathy'>Encephalomyopathy</a>,C3287A,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3287&alt=A&quart=3'><u>38.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
3288,MT-TL1,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,A3288G,tRNA Leu (UUR),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3288&alt=G&quart=3'><u>36.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
3290,MT-TL1,Poss. hypertension factor,T3290C,tRNA Leu (UUR),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3290&alt=C&quart=4'><u>1.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T3290C.html' target=_blank>0.227%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),124 (0),4
3291,MT-TL1,MELAS / Myopathy / Deafness+Cognitive Impairment,T3291C,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3291&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,18
3302,MT-TL1,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,A3302G,tRNA Leu (UUR),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3302&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,12
3303,MT-TL1,<a href='/MITOMAP/DiseaseList#MMC'>MMC</a>,C3303T,tRNA Leu (UUR),+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=3303&alt=T&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,15
4263,MT-TI,Maternally inherited essential hypertension,A4263G,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4263&alt=G&quart=2'><u>67.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),4
4267,MT-TI,MM / CPEO,A4267G,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4267&alt=G&quart=2'><u>71.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
4269,MT-TI,<a href='/MITOMAP/DiseaseList#FICP'>FICP</a>,A4269G,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4269&alt=G&quart=1'><u>82.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),9
4274,MT-TI,CPEO / Motor Neuron Disease,T4274C,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4274&alt=C&quart=1'><u>85.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
4277,MT-TI,HCM / Poss. hypertension factor,T4277C,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4277&alt=C&quart=4'><u>8.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.035%<br>(0.000%),19 (0),3
4279,MT-TI,Myoclonic epilepsy,A4279G,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4279&alt=G&quart=2'><u>54.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4281,MT-TI,Recurrent Myoglobinuria,A4281G,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4281&alt=G&quart=1'><u>87.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
4282,MT-TI,CPEO Plus,G4282A,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4282&alt=A&quart=1'><u>82.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4284,MT-TI,Varied familial presentation / spastic paraparesis,G4284A,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4284&alt=A&quart=3'><u>35.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),7
4285,MT-TI,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,T4285C,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4285&alt=C&quart=1'><u>84.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
4289,MT-TI,Retinopathy+diabetes+dysphagia+cerebral atrophy,T4289C,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4289&alt=C&quart=1'><u>84.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4290,MT-TI,"Progressive Encephalopathy / PEO,myopathy",T4290C,tRNA Ile,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4290&alt=C&quart=3'><u>47.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
4291,MT-TI,Hypomagnesemic Metabolic Syndrome,T4291C,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4291&alt=C&quart=3'><u>31.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4295,MT-TI,MHCM / Maternally inherited hypertension / Maternally inherited deafness,A4295G,tRNA Ile,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4295&alt=G&quart=3'><u>44.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.174%<br>(0.000%),95 (0),13
4296,MT-TI,Leigh Syndrome,G4296A,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4296&alt=A&quart=3'><u>46.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
4298,MT-TI,CPEO / MS,G4298A,tRNA Ile,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4298&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,10
4300,MT-TI,<a href='/MITOMAP/DiseaseList#MICM'>MICM</a>,A4300G,tRNA Ile,+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4300&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,11
4301,MT-TI,Patient with MELAS,A4301T,tRNA Ile,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4301&alt=T&quart=2'><u>59.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
4302,MT-TI,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,A4302G,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4302&alt=G&quart=3'><u>42.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4308,MT-TI,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G4308A,tRNA Ile,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4308&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
4309,MT-TI,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G4309A,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4309&alt=A&quart=2'><u>64.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
4314,MT-TI,Poss. hypertension factor,T4314C,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4314&alt=C&quart=4'><u>1.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.084%<br>(0.000%),46 (0),2
4316,MT-TI,HCM with hearing loss / poss. hypertension factor,A4316G,tRNA Ile,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4316&alt=G&quart=3'><u>37.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.040%<br>(0.000%),22 (0),4
4317,MT-TI,"Ptosis, deafness, stroke-like episodes",A4317del,tRNA Ile,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4317&alt=:&quart=4'><u>2.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.022%<br>(0.000%),12 (0),3
4317,MT-TI,FICP / poss. Hypertension / DEAF factor,A4317G,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4317&alt=G&quart=4'><u>2.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.060%<br>(0.000%),33 (0),13
4320,MT-TI,Mitochondrial Encephalocardiomyopathy,C4320T,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4320&alt=T&quart=3'><u>25.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),5
4322,MT-TI,mtDNA deletion and depletion with dilated cardiomyopathy,C4322del,tRNA Ile,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4322&alt=:&quart=1'><u>88.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4322,MT-TI,Idiopathic Dilated Cardiomopathy,C4322CC,tRNA Ile,-,+,Reported,-,0.005%<br>(0.000%),3 (0),1
4327,MT-TI,"Ataxia+, with RRF and COX deficiency",T4327C,tRNA Ile,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4327&alt=C&quart=2'><u>71.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
4332,MT-TQ,Encephalopathy / MELAS,G4332A,tRNA Gln,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4332&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
4336,MT-TQ,ADPD / Hearing Loss & Migraine / autism spectrum / intellectual disability,T4336C,tRNA Gln,+,+,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4336&alt=C&quart=3'><u>37.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T4336C.html' target=_blank>0.854%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),466 (0),28
4343,MT-TQ,Poss. hypertension factor,A4343G,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4343&alt=G&quart=4'><u>5.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.095%<br>(0.000%),52 (0),2
4345,MT-TQ,Poss. hypertension factor,C4345T,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4345&alt=T&quart=4'><u>13.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),1
4353,MT-TQ,Poss. hypertension factor,T4353C,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4353&alt=C&quart=3'><u>31.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.040%<br>(0.000%),22 (0),2
4363,MT-TQ,Metabolic syndrome and polycystic ovary syndrome / possibly associated w DEAF + RP + dev delay / hypertension / LHON,T4363C,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4363&alt=C&quart=4'><u>9.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.079%<br>(0.000%),43 (0),7
4369,MT-TQ,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,A4369AA,tRNA Gln,-,+,Reported,-,0.000%<br>(0.000%),,2
4372,MT-TQ,Suspected mito disease,C4372T,tRNA Gln,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4372&alt=T&quart=2'><u>71.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
4373,MT-TQ,Tic disorder / possibly LVNC-associated,T4373C,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4373&alt=C&quart=3'><u>29.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),3
4375,MT-TQ,Matrilineal hypertension risk factor,C4375T,tRNA Gln,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4375&alt=T&quart=4'><u>17.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.016%<br>(0.000%),9 (0),1
4381,MT-TQ,<a href='/MITOMAP/DiseaseList#LHON'>LHON</a>,A4381G,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4381&alt=G&quart=4'><u>15.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),3
4386,MT-TQ,Heart disease / myopathy / hypertension,T4386C,tRNA Gln,+,-,Conflicting reports,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4386&alt=C&quart=4'><u>6.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T4386C.html' target=_blank>0.332%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),181 (0),4
4387,MT-TQ,Poss. hypertension factor,C4387A,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4387&alt=A&quart=4'><u>12.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),1
4388,MT-TQ,Poss. hypertension factor; intellectual disability,A4388G,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4388&alt=G&quart=4'><u>0.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.117%<br>(0.000%),64 (0),3
4392,MT-TQ,Poss. hypertension factor,C4392T,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4392&alt=T&quart=4'><u>15.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.033%<br>(0.000%),18 (0),1
4395,MT-TQ,Poss. hypertension factor,A4395G,tRNA Gln,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4395&alt=G&quart=4'><u>0.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.046%<br>(0.000%),25 (0),3
4401,MT-NC2,Hypertension+Ventricular Hypertrophy,A4401G,NC2 Gln-Met spacer,+,-,Reported,N/A,0.005%<br>(0.000%),3 (0),3
4403,MT-TM,Mitochondrial myopathy,G4403A,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4403&alt=A&quart=1'><u>84.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4409,MT-TM,Mitochondrial myopathy,T4409C,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4409&alt=C&quart=3'><u>46.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
4410,MT-TM,Poss. hypertension factor,C4410A,tRNA Met,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4410&alt=A&quart=3'><u>32.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4412,MT-TM,Seizures with myopathy & retinopathy,G4412A,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4412&alt=A&quart=1'><u>76.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4414,MT-TM,Progressive external ophthalmoplegia and myopathy,T4414C,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4414&alt=C&quart=1'><u>86.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4415,MT-TM,EXIT & APS2,A4415G,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4415&alt=G&quart=3'><u>44.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
4435,MT-TM,LHON / LHON modulator / hypertension; autism spectrum; intellectual disability / hearing loss,A4435G,tRNA Met,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4435&alt=G&quart=4'><u>13.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.103%<br>(0.000%),56 (0),16
4437,MT-TM,"Hypotonia, seizure, muscle weakness, lactic acidosis, hearing loss",C4437T,tRNA Met,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4437&alt=T&quart=2'><u>67.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
4440,MT-TM,Mitochondrial myopathy,G4440A,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4440&alt=A&quart=2'><u>58.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
4450,MT-TM,Myopathy / MELAS / Leigh Syndrome,G4450A,tRNA Met,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4450&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
4452,MT-TM,Reported in tic disorder patient,T4452C,tRNA Met,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4452&alt=C&quart=4'><u>7.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T4452C.html' target=_blank>0.216%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),118 (0),1
4454,MT-TM,Possible contributor to mito dysfunction / hypertension,T4454C,tRNA Met,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4454&alt=C&quart=4'><u>0.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,0.392%<br>(0.000%),214 (0),4
4456,MT-TM,Poss. hypertension factor,C4456T,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4456&alt=T&quart=3'><u>32.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.015%<br>(0.000%),8 (0),2
4467,MT-TM,Maternally inherited hypertension,C4467A,tRNA Met,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=4467&alt=A&quart=1'><u>75.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5512,MT-TW,Maternally inherited hypertension,A5512G,tRNA Trp,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5512&alt=G&quart=3'><u>38.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),1
5513,MT-TW,Mitochondrial encephalomyopathy with RP,G5513A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5513&alt=A&quart=3'><u>32.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
5514,MT-TW,Neonatal onset mito disease,A5514G,tRNA Trp,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5514&alt=G&quart=4'><u>19.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.079%<br>(0.000%),43 (0),2
5521,MT-TW,Mitochondrial myopathy,G5521A,tRNA Trp,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5521&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
5522,MT-TW,Mitochondrial myopathy,G5522A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5522&alt=A&quart=1'><u>83.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5523,MT-TW,Leigh Syndrome,T5523G,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5523&alt=G&quart=1'><u>80.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5532,MT-TW,Gastrointestinal Syndrome,G5532A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5532&alt=A&quart=4'><u>19.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
5537,MT-TW,Leigh Syndrome,A5537insT,tRNA Trp,-,+,Cfrm,-,0.000%<br>(0.000%),,6
5538,MT-TW,<a href='/MITOMAP/DiseaseList#Encephalomyopathy'>Encephalomyopathy</a>,G5538A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5538&alt=A&quart=1'><u>76.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
5540,MT-TW,Encephalomyopathy / DEAF,G5540A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5540&alt=A&quart=2'><u>73.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
5541,MT-TW,MELAS+stroke-like episodes and cortical blindness+MRI shows occipital lobe infarct,C5541T,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5541&alt=T&quart=1'><u>84.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
5543,MT-TW,Mitochondrial myopathy,T5543C,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5543&alt=C&quart=3'><u>47.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,8
5545,MT-TW,HCM severe multisystem disorder,C5545T,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5545&alt=T&quart=2'><u>53.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5549,MT-TW,<a href='/MITOMAP/DiseaseList#DEMCHO'>DEMCHO</a>,G5549A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5549&alt=A&quart=1'><u>83.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5556,MT-TW,Combined OXPHOS defects,G5556A,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5556&alt=A&quart=3'><u>44.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5556,MT-TW,Mito encephalomyopathy,G5556C,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5556&alt=C&quart=3'><u>44.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5558,MT-TW,Reported in tic disorder patient,A5558G,tRNA Trp,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5558&alt=G&quart=3'><u>31.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.194%<br>(0.000%),106 (0),1
5559,MT-TW,Leigh Syndrome,A5559G,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5559&alt=G&quart=2'><u>70.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
5567,MT-TW,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,T5567C,tRNA Trp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5567&alt=C&quart=3'><u>32.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.099%<br>(0.000%),54 (0),3
5568,MT-TW,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A5568G,tRNA Trp,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5568&alt=G&quart=4'><u>9.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),2
5587,MT-TA,LHON / possible DEAF modifier / dilated cardiomyopathy / hypertension / tic disorder,T5587C,tRNA Ala,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5587&alt=C&quart=4'><u>12.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.064%<br>(0.000%),35 (0),10
5591,MT-TA,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G5591A,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5591&alt=A&quart=2'><u>68.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
5592,MT-TA,Coronary Heart Disease,A5592G,tRNA Ala,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5592&alt=G&quart=4'><u>0.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.053%<br>(0.000%),29 (0),2
5595,MT-TA,Reported in tic disorder patient,G5595A,tRNA Ala,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5595&alt=A&quart=2'><u>64.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
5601,MT-TA,Possible 4435G helper in maternally inherited hypertension,C5601T,tRNA Ala,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5601&alt=T&quart=4'><u>4.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/C5601T.html' target=_blank>0.976%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),533 (0),6
5610,MT-TA,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G5610A,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5610&alt=A&quart=3'><u>38.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5613,MT-TA,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,T5613C,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5613&alt=C&quart=2'><u>59.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5618,MT-TA,Hearing loss patient,T5618C,tRNA Ala,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5618&alt=C&quart=3'><u>28.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
5628,MT-TA,CPEO / DEAF enhancer / gout / tic disorder,T5628C,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5628&alt=C&quart=1'><u>78.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.170%<br>(0.000%),93 (0),7
5631,MT-TA,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G5631A,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5631&alt=A&quart=3'><u>43.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
5636,MT-TA,<a href='/MITOMAP/DiseaseList#PEO'>PEO</a>,T5636C,tRNA Ala,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5636&alt=C&quart=2'><u>73.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5641,MT-TA,Hearing loss patient,T5641C,tRNA Ala,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5641&alt=C&quart=3'><u>28.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.015%<br>(0.000%),8 (0),2
5650,MT-TA,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G5650A,tRNA Ala,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5650&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),10
5652,MT-TA,Dilated Cardiomyopathy,C5652G,tRNA Ala,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5652&alt=G&quart=2'><u>69.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5655,MT-TA,DEAF enhancer / Hypertension risk,T5655C,tRNA Ala,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5655&alt=C&quart=3'><u>26.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T5655C.html' target=_blank>0.582%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),318 (0),8
5658,MT-TN,Mitochondrial myopathy,T5658C,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5658&alt=C&quart=1'><u>94.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5667,MT-TN,Ptosis,G5667A,tRNA Asn,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5667&alt=A&quart=3'><u>44.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5669,MT-TN,Sporadic CPEO,G5669A,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5669&alt=A&quart=1'><u>88.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5672,MT-TN,EXIT+myalgia+CPEO with RRF,T5672C,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5672&alt=C&quart=4'><u>20.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5690,MT-TN,CPEO+ptosis+proximal myopathy,A5690G,tRNA Asn,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5690&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5692,MT-TN,CPEO / MM,T5692C,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5692&alt=C&quart=3'><u>46.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),4
5693,MT-TN,<a href='/MITOMAP/DiseaseList#Encephalomyopathy'>Encephalomyopathy</a>,T5693C,tRNA Asn,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5693&alt=C&quart=3'><u>31.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
5698,MT-TN,CPEO / MM,G5698A,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5698&alt=A&quart=3'><u>47.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),4
5702,MT-TN,Sporadic CPEO,A5702del,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5702&alt=:&quart=1'><u>89.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5703,MT-TN,CPEO / MM,G5703A,tRNA Asn,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5703&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),10
5709,MT-TN,Ophthalmoparesis+respiratory impairment,T5709C,tRNA Asn,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5709&alt=C&quart=3'><u>49.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5715,MT-TN,Hearing loss patient,A5715G,tRNA Asn,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5715&alt=G&quart=4'><u>12.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.022%<br>(0.000%),12 (0),1
5728,MT-TN,Multiorgan failure / myopathy,T5728C,tRNA Asn,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5728&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),5
5774,MT-TN,Reported in tic disorder patient,T5774C,tRNA Cys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5774&alt=C&quart=4'><u>0.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.112%<br>(0.000%),61 (0),1
5780,MT-TC,<a href='/MITOMAP/DiseaseList#SNHL'>SNHL</a>,G5780A,tRNA Cys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5780&alt=A&quart=3'><u>35.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.033%<br>(0.000%),18 (0),2
5783,MT-TC,Myopathy / deafness / gout / tic disorder,G5783A,tRNA Cys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5783&alt=A&quart=2'><u>66.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.075%<br>(0.000%),41 (0),4
5794,MT-TC,Hearing loss/ tic disorder,T5794C,tRNA Cys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5794&alt=C&quart=4'><u>16.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.013%<br>(0.000%),7 (0),6
5802,MT-TC,DEAF1555 increased penetrance / obesity risk,T5802C,tRNA Cys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5802&alt=C&quart=2'><u>58.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),7
5809,MT-TC,Hearing loss patient,G5809A,tRNA Cys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5809&alt=A&quart=2'><u>68.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
5814,MT-TC,Encephalopathy / gout,T5814C,tRNA Cys,-,+,Reported (L2b marker),<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5814&alt=C&quart=3'><u>38.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T5814C.html' target=_blank>0.289%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),158 (0),12
5816,MT-TC,Progressive Dystonia,A5816G,tRNA Cys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5816&alt=G&quart=2'><u>59.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
5819,MT-TC,Reported in tic disorder patient,T5819C,tRNA Cys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5819&alt=C&quart=4'><u>16.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5820,MT-TC,<a href='/MITOMAP/DiseaseList#MERRF'>MERRF</a>,C5820A,tRNA Cys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5820&alt=A&quart=2'><u>68.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5821,MT-TC,DEAF helper mut.,G5821A,tRNA Cys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5821&alt=A&quart=4'><u>20.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G5821A.html' target=_blank>0.612%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),334 (0),6
5822,MT-TC,Hearing loss patient,G5822A,tRNA Cys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5822&alt=A&quart=3'><u>30.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.011%<br>(0.000%),6 (0),3
5835,MT-TY,Patient with proximal myopathy,G5835A,tRNA Tyr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5835&alt=A&quart=2'><u>54.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
5843,MT-TY,FSGS / Mitochondrial Cytopathy,A5843G,tRNA Tyr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5843&alt=G&quart=4'><u>8.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A5843G.html' target=_blank>0.819%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),447 (0),2
5874,MT-TY,<a href='/MITOMAP/DiseaseList#EXIT'>EXIT</a>,T5874G,tRNA Tyr,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5874&alt=G&quart=3'><u>38.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5877,MT-TY,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,C5877T,tRNA Tyr,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5877&alt=T&quart=4'><u>24.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
5889,MT-TY,Multisystem mitochondrial disorder,A5889G,tRNA Tyr,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=5889&alt=G&quart=2'><u>66.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
7445,MT-TS1 precursor,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A7445C,tRNA Ser (UCN) precursor,+,-,Reported,-,0.027%<br>(0.000%),15 (0),7
7445,MT-TS1 precursor,<a href='/MITOMAP/DiseaseList#SNHL'>SNHL</a>,A7445G,tRNA Ser (UCN) precursor,+,+,Cfrm,-,0.002%<br>(0.000%),1 (0),37
7445,MT-TS1 precursor,<a href='/MITOMAP/DiseaseList#SNHL'>SNHL</a>,A7445T,tRNA Ser (UCN) precursor,+,-,Reported,-,0.005%<br>(0.000%),3 (0),1
7451,MT-TS1,CPEO+ptosis,A7451T,tRNA Ser (UCN) precursor,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7451&alt=T&quart=1'><u>80.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
7453,MT-TS1,"Fatal neonatal lactic acidosis / Neonatal lactic acidosis, exercise intolerance, mild ID",G7453A,tRNA Ser (UCN),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7453&alt=A&quart=2'><u>68.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
7456,MT-TS1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,A7456G,tRNA Ser (UCN),+,-,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7456&alt=G&quart=4'><u>16.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.027%<br>(0.000%),15 (0),1
7458,MT-TS1,<a href='/MITOMAP/DiseaseList#PEO'>PEO</a>,G7458A,tRNA Ser (UCN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7458&alt=A&quart=1'><u>86.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
7462,MT-TS1,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,C7462T,tRNA Ser (UCN),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7462&alt=T&quart=4'><u>11.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.011%<br>(0.000%),6 (0),1
7471,MT-TS1,Maternally inherited hypertension / deafness,C7471del,tRNA Ser (UCN),nr,nr,Reported (=7466d),<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7471&alt=:&quart=4'><u>4.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.026%<br>(0.000%),14 (0),3
7471,MT-TS1,PEM / AMDF / Motor neuron disease-like,C7471CC,tRNA Ser (UCN),+,+,Cfrm,-,0.013%<br>(0.000%),7 (0),32
7472,MT-TS1,MM / DMDF modulator,A7472C,tRNA Ser (UCN),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7472&alt=C&quart=4'><u>3.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),4
7472,MT-TS1,PEM / AMDF / Motor neuron disease-like,A7472CA,tRNA Ser (UCN),+,+,See 7471insC,-,0.000%<br>(0.000%),,1
7474,MT-TS1,Hearing loss and epilepsy,A7474del,tRNA Ser (UCN),nr,nr,Reported (=7474d),<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7474&alt=:&quart=3'><u>34.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),1
7474,MT-TS1,Hearing loss patient,A7474G,tRNA Ser (UCN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7474&alt=G&quart=4'><u>0.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),1
7480,MT-TS1,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,T7480G,tRNA Ser (UCN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7480&alt=G&quart=3'><u>46.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
7486,MT-TS1,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G7486A,tRNA Ser (UCN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7486&alt=A&quart=2'><u>50.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
7492,MT-TS1,Hypertension / hearing loss risk factor,C7492T,tRNA Ser (UCN),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7492&alt=T&quart=4'><u>0.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.015%<br>(0.000%),8 (0),2
7496,MT-TS1,Hearing Loss,T7496C,tRNA Ser (UCN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7496&alt=C&quart=2'><u>58.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.005%<br>(0.000%),3 (0),2
7497,MT-TS1,MM / EXIT,G7497A,tRNA Ser (UCN),+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7497&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),9
7501,MT-TS1,Cardiovascular disease; renal disease patient,T7501A,tRNA Ser (UCN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7501&alt=A&quart=4'><u>1.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
7502,MT-TS1,Reported in tic disorder patient,C7502T,tRNA Ser (UCN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7502&alt=T&quart=4'><u>8.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),1
7505,MT-TS1,Maternally inherited hearing loss,T7505C,tRNA Ser (UCN),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7505&alt=C&quart=2'><u>58.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
7506,MT-TS1,PEO with hearing loss,G7506A,tRNA Ser (UCN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7506&alt=A&quart=1'><u>81.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
7510,MT-TS1,<a href='/MITOMAP/DiseaseList#SNHL'>SNHL</a>,T7510C,tRNA Ser (UCN),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7510&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),14
7511,MT-TS1,SNHL/Deafness,T7511C,tRNA Ser (UCN),+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7511&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),25
7512,MT-TS1,PEM / MERME  / MELAS,T7512C,tRNA Ser (UCN),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7512&alt=C&quart=2'><u>64.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,13
7519,MT-TD,Deafness-associated,A7519del,tRNA Asp,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7519&alt=:&quart=3'><u>36.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
7520,MT-TD,Sporadic bilateral optic neuropathy,G7520A,tRNA Asp,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7520&alt=A&quart=2'><u>54.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
7526,MT-TD,Mitochondrial myopathy,A7526G,tRNA Asp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7526&alt=G&quart=2'><u>50.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
7539,MT-TD,Multisystemic mitochondrial disorder,C7539T,tRNA Asp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7539&alt=T&quart=1'><u>93.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
7543,MT-TD,<a href='/MITOMAP/DiseaseList#MEPR'>MEPR</a>,A7543G,tRNA Asp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7543&alt=G&quart=2'><u>67.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.097%<br>(0.000%),53 (0),3
7551,MT-TD,DEAF increased penetrance (1555G helper),A7551G,tRNA Asp,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7551&alt=G&quart=3'><u>28.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),4
7554,MT-TD,Myopathy+ataxia+nystagmus+migraines+lactic acidosis,G7554A,tRNA Asp,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7554&alt=A&quart=2'><u>71.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
7566,MT-TD,Unspecified patient from clinical lab,G7566A,tRNA Asp,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=7566&alt=A&quart=2'><u>65.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
8296,MT-TK,DMDF / MERRF / HCM / epilepsy / hearing loss,A8296G,tRNA Lys,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8296&alt=G&quart=2'><u>72.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.070%<br>(0.000%),38 (0),20
8299,MT-TK,PEO + respiratory impairment,G8299A,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8299&alt=A&quart=2'><u>63.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
8302,MT-TK,Encephalopathy,A8302T,tRNA Lys,+,-,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8302&alt=T&quart=4'><u>15.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
8304,MT-TK,Epilepsy+ataxia+visual disturbance+deafness,G8304A,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8304&alt=A&quart=1'><u>89.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
8305,MT-TK,Mitochondrial myopathy,C8305T,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8305&alt=T&quart=2'><u>74.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,4
8306,MT-TK,Severe adult-onset multisymptom myopathy / Myoclonic epilepsy,T8306C,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8306&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
8311,MT-TK,Poss. hypertension factor,T8311C,tRNA Lys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8311&alt=C&quart=4'><u>6.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.108%<br>(0.000%),59 (0),2
8313,MT-TK,MNGIE / Progressive mito cytopathy,G8313A,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8313&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),6
8316,MT-TK,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,T8316C,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8316&alt=C&quart=1'><u>80.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
8319,MT-TK,Kearns-Sayre syndrome,A8319G,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8319&alt=G&quart=2'><u>69.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
8326,MT-TK,Mitochondrial Cytopathy,A8326G,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8326&alt=G&quart=3'><u>46.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
8328,MT-TK,Mito Encephalopathy / EXIT with myopathy and ptosis,G8328A,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8328&alt=A&quart=1'><u>83.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,6
8332,MT-TK,Dystonia and stroke-like episodes,A8332G,tRNA Lys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8332&alt=G&quart=2'><u>62.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
8337,MT-TK,Poss. hypertension factor,T8337C,tRNA Lys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8337&alt=C&quart=4'><u>6.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T8337C.html' target=_blank>0.315%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),172 (0),2
8339,MT-TK,Hearing loss patient,A8339G,tRNA Lys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8339&alt=G&quart=3'><u>47.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
8340,MT-TK,Myopathy / Exercise Intolerance / Eye disease+SNHL,G8340A,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8340&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,8
8342,MT-TK,PEO and Myoclonus,G8342A,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8342&alt=A&quart=1'><u>77.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
8343,MT-TK,Metabolic syndrome and polycystic ovary syndrome / possible PD risk factor / deafness,A8343G,tRNA Lys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8343&alt=G&quart=4'><u>4.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.106%<br>(0.000%),58 (0),5
8344,MT-TK,MERRF; Other - LD / Depressive mood disorder / leukoencephalopathy / HiCM,A8344G,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8344&alt=G&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),136
8346,MT-TK,Rett Syndrome,C8346del,tRNA Lys,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8346&alt=:&quart=4'><u>3.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.013%<br>(0.000%),7 (0),1
8347,MT-TK,Poss. hypertension factor,A8347G,tRNA Lys,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8347&alt=G&quart=4'><u>2.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.033%<br>(0.000%),18 (0),3
8348,MT-TK,Cardiomyopathy / SNHL / poss. hypertension factor,A8348G,tRNA Lys,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8348&alt=G&quart=3'><u>33.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.207%<br>(0.000%),113 (0),9
8355,MT-TK,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,T8355C,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8355&alt=C&quart=2'><u>67.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
8356,MT-TK,<a href='/MITOMAP/DiseaseList#MERRF'>MERRF</a>,T8356C,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8356&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,13
8357,MT-TK,Multiple symmetric lipomatosis,T8357C,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8357&alt=C&quart=2'><u>59.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
8361,MT-TK,<a href='/MITOMAP/DiseaseList#MERRF'>MERRF</a>,G8361A,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8361&alt=A&quart=2'><u>64.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
8362,MT-TK,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,T8362G,tRNA Lys,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8362&alt=G&quart=1'><u>93.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,6
8363,MT-TK,MICM+DEAF / MERRF / Autism / Leigh Syndrome / Ataxia+Lipomas,G8363A,tRNA Lys,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=8363&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,23
9997,MT-TG,Unspecified patient from clinical lab,T9997A,tRNA Gly,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=9997&alt=A&quart=1'><u>95.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
9997,MT-TG,<a href='/MITOMAP/DiseaseList#MHCM'>MHCM</a>,T9997C,tRNA Gly,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=9997&alt=C&quart=1'><u>80.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),5
10003,MT-TG,Hypertension / maternally inherited diabetes / hearing loss,T10003C,tRNA Gly,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10003&alt=C&quart=4'><u>0.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.016%<br>(0.000%),9 (0),5
10005,MT-TG,Hearing loss patient,A10005G,tRNA Gly,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10005&alt=G&quart=4'><u>9.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.038%<br>(0.000%),21 (0),3
10006,MT-TG,CIPO / Encephalopathy,A10006G,tRNA Gly,+,-,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10006&alt=G&quart=4'><u>19.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),5
10010,MT-TG,<a href='/MITOMAP/DiseaseList#PEM'>PEM</a>,T10010C,tRNA Gly,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10010&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,11
10014,MT-TG,<a href='/MITOMAP/DiseaseList#Myopathy'>Myopathy</a>,G10014A,tRNA Gly,+,-,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10014&alt=A&quart=2'><u>60.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
10019,MT-TG,Hearing loss patient,C10019T,tRNA Gly,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10019&alt=T&quart=2'><u>50.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
10044,MT-TG,<a href='/MITOMAP/DiseaseList#SIDS'>SIDS</a>,A10044G,tRNA Gly,-,+,Unclear,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10044&alt=G&quart=3'><u>34.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.260%<br>(0.000%),142 (0),9
10055,MT-TG,Tic disorder patient / hearing loss patient,A10055G,tRNA Gly,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10055&alt=G&quart=3'><u>29.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.020%<br>(0.000%),11 (0),5
10057,MT-TG,Hearing loss patient,T10057C,tRNA Gly,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10057&alt=C&quart=3'><u>38.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),2
10406,MT-TR,Mitochondrial myopathy,G10406A,tRNA Arg,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10406&alt=A&quart=2'><u>72.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
10408,MT-TR,Unspecified patient from clinical lab,T10408C,tRNA Arg,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10408&alt=C&quart=2'><u>64.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10411,MT-TR,Dilated Cardiomyopathy,A10411T,tRNA Arg,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10411&alt=T&quart=3'><u>26.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10415,MT-TR,Dilated Cardiomyopathy,T10415C,tRNA Arg,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10415&alt=C&quart=1'><u>76.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10437,MT-TR,Mitochondrial myopathy,G10437A,tRNA Arg,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10437&alt=A&quart=2'><u>51.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10438,MT-TR,Progressive Encephalopathy,A10438G,tRNA Arg,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10438&alt=G&quart=3'><u>46.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10438,MT-TR,Non-dystrophic myopathy,A10438T,tRNA Arg,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10438&alt=T&quart=3'><u>46.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10450,MT-TR,Combined OXPHOS defects & severe multisystem disorder,A10450G,tRNA Arg,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10450&alt=G&quart=2'><u>69.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
10454,MT-TR,DEAF helper mut.,T10454C,tRNA Arg,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10454&alt=C&quart=4'><u>4.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T10454C.html' target=_blank>0.346%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),189 (0),5
10460,MT-TR,Unspecified patient from clinical lab,T10460C,tRNA Arg,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=10460&alt=C&quart=2'><u>72.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12141,MT-TR,Reported in tic disorder patient,A12141G,tRNA His,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12141&alt=G&quart=4'><u>22.80%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.015%<br>(0.000%),8 (0),1
12146,MT-TH,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,A12146G,tRNA His,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12146&alt=G&quart=2'><u>61.60%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12147,MT-TH,MERRF-MELAS / Encephalopathy,G12147A,tRNA His,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12147&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
12148,MT-TH,"Developmental delay, optic atrophy, cataract, hearing loss, myopathy",T12148C,tRNA His,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12148&alt=C&quart=2'><u>74.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
12167,MT-TH,Hearing loss patient,T12167C,tRNA His,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12167&alt=C&quart=4'><u>24.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
12182,MT-TH,Sclerosis-like symptoms + white matter alterations,A12182G,tRNA His,+,-,Reported as VUS,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12182&alt=G&quart=3'><u>46.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),1
12183,MT-TH,RP + DEAF,G12183A,tRNA His,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12183&alt=A&quart=2'><u>70.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),3
12187,MT-TH,Asthenozoospermia,C12187A,tRNA His,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12187&alt=A&quart=4'><u>15.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12188,MT-TH,Hearing loss patient,T12188C,tRNA His,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12188&alt=C&quart=4'><u>6.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.051%<br>(0.000%),28 (0),3
12192,MT-TH,MICM / possible G15927A deafness modulator,G12192A,tRNA His,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12192&alt=A&quart=4'><u>4.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G12192A.html' target=_blank>0.214%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),117 (0),5
12201,MT-TH,Maternally inherited non-syndromic deafness,T12201C,tRNA His,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12201&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),9
12206,MT-TH,MELAS-like  encephalopathy+bilateral optic atrophy,C12206T,tRNA His,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12206&alt=T&quart=3'><u>44.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12207,MT-TS2,Myopathy / Encephalopathy,G12207A,tRNA Ser (AGY),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12207&alt=A&quart=1'><u>76.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
12224,MT-TS2,DEAF helper mutation,C12224T,tRNA Ser (AGY),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12224&alt=T&quart=3'><u>30.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),2
12235,MT-TS2,Hearing loss patient,T12235C,tRNA Ser (AGY),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12235&alt=C&quart=3'><u>27.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,0.408%<br>(0.000%),223 (0),2
12236,MT-TS2,<a href='/MITOMAP/DiseaseList#DEAF'>DEAF</a>,G12236A,tRNA Ser (AGY),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12236&alt=A&quart=4'><u>2.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G12236A.html' target=_blank>0.674%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),368 (0),5
12246,MT-TS2,<a href='/MITOMAP/DiseaseList#CIPO'>CIPO</a>,C12246A,tRNA Ser (AGY),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12246&alt=A&quart=4'><u>3.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.005%<br>(0.000%),3 (0),2
12258,MT-TS2,DMDF / RP+SNHL,C12258A,tRNA Ser (AGY),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12258&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),7
12258,MT-TS2,Unspecified patient from clinical lab,C12258T,tRNA Ser (AGY),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12258&alt=T&quart=1'><u>81.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12261,MT-TS2,Myopathy+epilepsy+retinal degeneration+DEAF,T12261C,tRNA Ser (AGY),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12261&alt=C&quart=2'><u>65.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12262,MT-TS2,Progressive MM+Deafness+Seizures,C12262A,tRNA Ser (AGY),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12262&alt=A&quart=1'><u>84.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
12264,MT-TS2,Multisystem Disease with Cataracts / Myopathy+epilepsy+DEAF+atypical autism,C12264T,tRNA Ser (AGY),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12264&alt=T&quart=1'><u>79.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
12276,MT-TL2,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G12276A,tRNA Leu (CUN),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12276&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),4
12279,MT-TL2,Reported in tic disorder patient,A12279G,tRNA Leu (CUN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12279&alt=G&quart=4'><u>5.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A12279G.html' target=_blank>0.476%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),260 (0),1
12280,MT-TL2,<a href='/MITOMAP/DiseaseList#Hypertension'>Hypertension</a>,A12280G,tRNA Leu (CUN),+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12280&alt=G&quart=4'><u>6.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.152%<br>(0.000%),83 (0),2
12283,MT-TL2,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G12283A,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12283&alt=A&quart=3'><u>43.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),2
12293,MT-TL2,Axial mitochondrial myopathy / EXIT+myalgia+ptosis,G12293A,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12293&alt=A&quart=2'><u>66.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
12294,MT-TL2,CPEO / EXIT+Ophthalmoplegia,G12294A,tRNA Leu (CUN),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12294&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
12297,MT-TL2,Dilated Cardiomyopathy / Leigh Syndrome / Failure to Thrive & LA,T12297C,tRNA Leu (CUN),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12297&alt=C&quart=3'><u>47.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.082%<br>(0.000%),45 (0),6
12299,MT-TL2,<a href='/MITOMAP/DiseaseList#MELAS'>MELAS</a>,A12299C,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12299&alt=C&quart=2'><u>53.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12300,MT-TL2,3243 suppressor mutant,G12300A,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12300&alt=A&quart=2'><u>51.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
12308,MT-TL2,CPEO / Stroke / CM / Breast & Renal & Prostate Cancer Risk / Altered brain pH /sCJD,A12308G,tRNA Leu (CUN),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12308&alt=G&quart=3'><u>42.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A12308G.html' target=_blank>12.412%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),6776 (0),20
12311,MT-TL2,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,T12311C,tRNA Leu (CUN),+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12311&alt=C&quart=3'><u>34.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.104%<br>(0.000%),57 (0),4
12313,MT-TL2,<a href='/MITOMAP/DiseaseList#FSHD'>FSHD</a>,T12313C,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12313&alt=C&quart=2'><u>73.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12315,MT-TL2,"CPEO / KSS / possible carotid atherosclerosis risk, trend toward myocardial infarction risk",G12315A,tRNA Leu (CUN),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12315&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,15
12316,MT-TL2,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G12316A,tRNA Leu (CUN),-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12316&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
12317,MT-TL2,CPEO+ptosis+myopathy+exercise intolerance+diabetes,T12317C,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12317&alt=C&quart=3'><u>41.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
12320,MT-TL2,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,A12320G,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12320&alt=G&quart=3'><u>37.30%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,7
12325,MT-TL2,Hearing loss patient,C12325:,tRNA Leu (CUN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12325&alt=:&quart=1'><u>91.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12334,MT-TL2,<a href='/MITOMAP/DiseaseList#CPEO'>CPEO</a>,G12334A,tRNA Leu (CUN),-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12334&alt=A&quart=2'><u>63.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
12335,MT-TL2,Unspecified patient from clinical lab,T12335C,tRNA Leu (CUN),nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=12335&alt=C&quart=2'><u>60.20%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14674,MT-TE,Reversible COX deficiency myopathy,T14674C,tRNA Glu,+,-,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14674&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),10
14674,MT-TE,Reversible COX deficiency myopathy,T14674G,tRNA Glu,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14674&alt=G&quart=3'><u>29.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14680,MT-TE,Mitochondrial encephalomyopathy,C14680A,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14680&alt=A&quart=3'><u>35.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14685,MT-TE,Cataracts w spastic paraparesis & ataxia,G14685A,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14685&alt=A&quart=1'><u>77.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14687,MT-TE,Mito myopathy w respiratory failure; intellectual disability,A14687G,tRNA Glu,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14687&alt=G&quart=4'><u>7.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A14687G.html' target=_blank>0.582%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),318 (0),5
14692,MT-TE,LHON helper / Maternally inherited diabetes & deafness /tic disorder,A14692G,tRNA Glu,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14692&alt=G&quart=4'><u>2.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.033%<br>(0.000%),18 (0),5
14693,MT-TE,MELAS / LHON / DEAF / hypertension helper,A14693G,tRNA Glu,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14693&alt=G&quart=3'><u>39.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A14693G.html' target=_blank>0.601%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),328 (0),16
14696,MT-TE,Progressive Encephalopathy,A14696G,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14696&alt=G&quart=4'><u>22.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.139%<br>(0.000%),76 (0),2
14709,MT-TE,MM+DMDF / Encephalomyopathy / Dementia+diabetes+ophthalmoplegia,T14709C,tRNA Glu,+,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14709&alt=C&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),28
14710,MT-TE,Encephalomyopathy + Retinopathy,G14710A,tRNA Glu,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14710&alt=A&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,6
14721,MT-TE,Isolated complex I deficiency,G14721A,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14721&alt=A&quart=1'><u>82.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14723,MT-TE,CPEO + Myopathy,T14723C,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14723&alt=C&quart=2'><u>73.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
14724,MT-TE,Mito Leukoencephalopathy,G14724A,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14724&alt=A&quart=1'><u>88.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
14728,MT-TE,Late-onset mitochondrial encephalomyopathy,T14728C,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14728&alt=C&quart=3'><u>48.50%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
14739,MT-TE,<a href='/MITOMAP/DiseaseList#EXIT'>EXIT</a>,G14739A,tRNA Glu,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=14739&alt=A&quart=2'><u>62.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),4
15894,MT-TT,Gout,G15894A,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15894&alt=A&quart=3'><u>28.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.062%<br>(0.000%),34 (0),2
15897,MT-TT,Maternally inherited diabetes (MID),G15897A,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15897&alt=A&quart=1'><u>81.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
15901,MT-TT,Hearing loss patient,A15901G,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15901&alt=G&quart=4'><u>15.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.016%<br>(0.000%),9 (0),1
15902,MT-TT,Hearing loss patient,A15902G,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15902&alt=G&quart=4'><u>7.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.016%<br>(0.000%),9 (0),1
15908,MT-TT,DEAF helper mutation,T15908C,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15908&alt=C&quart=3'><u>28.00%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/T15908C.html' target=_blank>0.343%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),187 (0),4
15909,MT-TT,<a href='/MITOMAP/DiseaseList#Hypertension'>Hypertension</a>,A15909G,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15909&alt=G&quart=3'><u>25.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),3
15910,MT-TT,Tic disorder patient / hearing loss patient / coronary heart disease,C15910T,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15910&alt=T&quart=3'><u>25.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.049%<br>(0.000%),27 (0),3
15915,MT-TT,<a href='/MITOMAP/DiseaseList#Encephalomyopathy'>Encephalomyopathy</a>,G15915A,tRNA Thr,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15915&alt=A&quart=2'><u>73.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),4
15923,MT-TT,LIMM / MERRF / mito disease,A15923G,tRNA Thr,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15923&alt=G&quart=3'><u>46.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
15924,MT-TT,<a href='/MITOMAP/DiseaseList#LIMM'>LIMM</a>,A15924G,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15924&alt=G&quart=4'><u>22.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A15924G.html' target=_blank>3.484%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),1902 (0),7
15926,MT-TT,Hearing loss patient,C15926T,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15926&alt=T&quart=4'><u>0.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.018%<br>(0.000%),10 (0),2
15927,MT-TT,LHON / Multiple Sclerosis / DEAF1555 increased penetrance / CHD,G15927A,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15927&alt=A&quart=4'><u>16.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G15927A.html' target=_blank>0.850%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),464 (0),18
15928,MT-TT,Multiple Sclerosis / idiopathic repeat miscarriage / AD protection,G15928A,tRNA Thr,+,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15928&alt=A&quart=4'><u>20.20%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/G15928A.html' target=_blank>4.880%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),2664 (0),8
15933,MT-TT,Suspected mito disease,G15933A,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15933&alt=A&quart=2'><u>66.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
15942,MT-TT,Possibly LVNC-associated,T15942C,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15942&alt=C&quart=3'><u>28.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,0.744%<br>(0.000%),406 (0),2
15944,MT-TT,<a href='/MITOMAP/DiseaseList#MM'>MM</a>,T15944:,tRNA Thr,+,-,Conflicting reports,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15944&alt=:&quart=4'><u>19.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,1.407%<br>(0.000%),768 (0),3
15948,MT-TT,Reported in tic disorder patient,A15948G,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15948&alt=G&quart=3'><u>29.90%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.004%<br>(0.000%),2 (0),1
15950,MT-TT,Dopaminergic nerve cell death (PD) / tic disorder,G15950A,tRNA Thr,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15950&alt=A&quart=2'><u>54.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.005%<br>(0.000%),3 (0),3
15951,MT-TT,LHON / LHON modulator,A15951G,tRNA Thr,+,-,Conflicting reports,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15951&alt=G&quart=4'><u>23.70%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-asterisk' style='color:green' aria-hidden='true'></i></span>,<span style='white-space:nowrap;'><a href='/haploinfo_genbank/A15951G.html' target=_blank>0.727%</a>&nbsp;<img src='/images/flag.png'></span><br>(0.000%),397 (0),9
15952,MT-TT,Reported in tic disorder patient,C15952T,tRNA Thr,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15952&alt=T&quart=3'><u>39.40%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.009%<br>(0.000%),5 (0),1
15958,MT-TP,Severe myopathy / EXIT,A15958T,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15958&alt=T&quart=1'><u>93.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
15965,MT-TP,Dopaminergic nerve cell death (PD),A15965G,tRNA Pro,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15965&alt=G&quart=4'><u>2.10%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.016%<br>(0.000%),9 (0),2
15967,MT-TP,MERRF-like disease,G15967A,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15967&alt=A&quart=1'><u>78.90%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
15975,MT-TP,Ataxia+RP+deafness,C15975T,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15975&alt=T&quart=1'><u>78.30%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
15986,MT-TP,LHON modulator,G15986GG,tRNA Pro,,,Reported,-,0.000%<br>(0.000%),,3
15990,MT-TP,MM / PEO,C15990T,tRNA Pro,-,+,Cfrm,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15990&alt=T&quart=0'><u>Pathogenic</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,5
15992,MT-TP,Tic disorder patient / hearing loss patient,A15992G,tRNA Pro,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15992&alt=G&quart=4'><u>17.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.007%<br>(0.000%),4 (0),2
15992,MT-TP,Exercise-induced muscle swelling and fatigue,A15992T,tRNA Pro,+,-,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15992&alt=T&quart=4'><u>17.60%</u></a> <i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i><i class='fa fa-arrow-down' style='color:green' aria-hidden='true'></i></span>,0.002%<br>(0.000%),1 (0),1
15995,MT-TP,Mitochondrial cytopathy,G15995A,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15995&alt=A&quart=1'><u>80.00%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,3
15997,MT-TP,Hearing loss patient,T15997C,tRNA Pro,nr,nr,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15997&alt=C&quart=2'><u>60.10%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
15998,MT-TP,Mitochondrial myopathy,A15998T,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=15998&alt=T&quart=2'><u>57.50%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
16002,MT-TP,Mitochondrial cytopathy,T16002C,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=16002&alt=C&quart=1'><u>75.80%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,2
16015,MT-TP,Mitochondrial myopathy,T16015C,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=16015&alt=C&quart=2'><u>50.40%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
16018,MT-TP,"Dilated cardiomyopathy (15 bp dup), alternate notation",T16018TTCTCTGTTCTTTCAT,tRNA Pro,-,+,Reported,-,0.000%<br>(0.000%),,2
16021,MT-TP,Mitochondrial myopathy,16021_16022delCT,tRNA Pro,-,+,Reported,-,0.000%<br>(0.000%),,1
16023,MT-TP,Migraine +pigmentary retinopathy +deafness +leukariosis,G16023A,tRNA Pro,-,+,Reported,<span style='display:inline-block;white-space:nowrap;'><a href='/cgi-bin/mitotip?pos=16023&alt=A&quart=1'><u>83.70%</u></a> <i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i><i class='fa fa-arrow-up' style='color:red' aria-hidden='true'></i></span>,0.000%<br>(0.000%),,1
16032,MT-CR,"Dilated cardiomyopathy (15 bp dup), alternate notation",T16032TTCTCTGTTCTTTCAT,tRNA Pro / CR,-,+,Reported,-,0.002%<br>(0.000%),1 (0),1
